Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sapporo Clinical Laboratory's EV-to-FCF or its related term are showing as below:
TSE:9776'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.77 Med: 0.4 Max: 27.71
Current: 27.71
During the past 13 years, the highest EV-to-FCF of Sapporo Clinical Laboratory was 27.71. The lowest was -10.77. And the median was 0.40.
TSE:9776's EV-to-FCF is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 18.215
vs TSE:9776: 27.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sapporo Clinical Laboratory (TSE:9776) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sapporo Clinical Laboratory's PE Ratio (TTM) for today is calculated as:
Sapporo Clinical Laboratory's share price for today is 円1960.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sapporo Clinical Laboratory's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was 円157.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sapporo Clinical Laboratory EV-to-FCF Related Terms
Sapporo Clinical Laboratory EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory EV-to-FCF Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sapporo Clinical Laboratory EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sapporo Clinical Laboratory's EV-to-FCF falls into.
Sapporo Clinical Laboratory's current Enterprise Value is 円4,780 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sapporo Clinical Laboratory's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was 円173 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory (TSE:9776) has a EV-to-FCF of 27.71 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sapporo Clinical Laboratory and its competitors. This is 6828% above median its historical median of 0.40.
Is Sapporo Clinical Laboratory's EV-to-FCF too high?
Sapporo Clinical Laboratory's current EV-to-FCF of 27.71 is 6828% above median its 10-year median of 0.40. The Healthcare Providers & Services industry median EV-to-FCF is 18.22. Sapporo Clinical Laboratory's value of 27.71 is 52.1% above this industry median. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's EV-to-FCF compare to competitors?
Sapporo Clinical Laboratory's EV-to-FCF of 27.71 can be compared against companies in the Healthcare Providers & Services industry. The industry median EV-to-FCF is 18.22. Sapporo Clinical Laboratory's value of 27.71 is 52.1% above this benchmark. While the company's 10-year median is 0.40 vs. the industry median of 18.22, Sapporo Clinical Laboratory has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.22, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sapporo Clinical Laboratory's current EV-to-FCF of 27.71 is 52.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sapporo Clinical Laboratory and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sapporo Clinical Laboratory's current EV-to-FCF is 27.71, which is 6828% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current EV-to-FCF of 27.71. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current EV-to-FCF is 27.71, which is 6828% above median its 10-year median of 0.40 and 52.1% above the Healthcare Providers & Services industry median of 18.22. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current EV-to-FCF is 27.71 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?
Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued.
The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.
Key valuation signals for TSE:9776:
EV-to-FCF: 27.71 (6828% above median its 10-year median of 0.40)
GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
Industry Position: 52.1% above the Healthcare Providers & Services median
No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score
Get the complete analysis for TSE:9776
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9776 has been successfully added to your 
